Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352831 · ClinicalTrials.gov registry record · Phase 1
Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02352831 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 16 participants.
The verdict
NCT02352831, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
There are two parts to this study: the goal of the first part of the study is to find the best dose of tosedostat when given in combination with capecitabine. The goal of the second part of the study is to look at how participants respond to treatment with tosedostat and capecitabine.
Interventions
- DRUG Capecitabine
- DRUG Tosedostat
- PROCEDURE Fresh tissue biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-08-31 |
| Est. Completion | 2018-10-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02352831
The ClinicalTrials.gov registry entry for NCT02352831 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT02352831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02352831 about?
NCT02352831 is a clinical study titled "Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma". There are two parts to this study: the goal of the first part of the study is to find the best dose of tosedostat when given in combination with capecitabine. The goal of the second part of the study is to look at how participants respond to treatment with tosedostat and capecitabine.
What is the current status of trial NCT02352831?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-08-31. Estimated completion is 2018-10-19.
What interventions are being tested in trial NCT02352831?
The interventions under investigation include: Capecitabine (DRUG), Tosedostat (DRUG), Fresh tissue biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02352831?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.